Management of Hepatitis B Infection

  • Authors: Harry L. A. Janssen, MD, PhD; Milan J. Sonneveld, MD, PhD, MSc (More Info)
  • Editor In Chief: Stefan Zeuzem, MD
  • Last Reviewed: 5/25/18 (What's New)

Summary

  • Emergence of viral resistance to nucleos(t)ide analogue therapy is dependent on HBV activity, the drug’s antiviral potency and resistance barrier, and host (immune) factors
  • The barrier to resistance varies significantly across the different agents and depends on the number of mutations in the viral genome that are required to confer resistance
    • Drugs with a low or intermediate barrier to resistance (lamivudine, adefovir, and telbivudine) require only a single or a few mutations in the viral genome for resistance to occur
  • Managing Lamivudine Resistance
      Managing Adefovir Resistance
        Managing Telbivudine Resistance
          Managing Entecavir and Tenofovir Resistance

          Action required